Skip to main content
BIIB
NASDAQ Life Sciences

Diranersen Shows Growing Benefit at Two Years in Early Alzheimer's

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$253
Mkt Cap
$37.072B
52W Low
$160.365
52W High
$261
52W Position info
58% above low
Off High info
3.1% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BIIB sits 58% above its 52-week low of $160.365.

Summary

Biogen's tau-targeting antisense therapy diranersen showed increasing clinical benefit at two years in the Phase 2 CELIA study, with the 60 mg twice-yearly regimen producing the largest effects. The CDR-SB treatment effect grew from 26% at Week 76 to 38% at Week 96, a 1.09-point difference that clears the one-point threshold clinicians consider meaningful. ADAS-Cog13 separation widened from 42% to 54%, and function measures improved as well, with no new safety signals through two years. The data were presented at CTAD 2026 and support advancing diranersen into Phase 3; the drug holds FDA Fast Track designation but remains investigational. This is a pipeline readout, not a commercial event, so the near-term stock impact depends on how much credibility the market assigns to a Phase 2 tau program ahead of pivotal testing.

At the time of this announcement, BIIB was trading at $253.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.1B. The 52-week trading range was $160.36 to $261.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Nov 09, 2026, 1:02 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $248.35
Real-time Price: $253.00 info
Change: +$4.65 (+2%) info
Market Cap: $37.072B info
BIIB
Oct 28, 2026, 6:23 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $253.00 info
Change: +$0.270 (+0.11%) info
Market Cap: $37.072B info
BIIB
Oct 28, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $253.00 info
Change: +$0.270 (+0.11%) info
Market Cap: $37.072B info
BIIB
Oct 28, 2026, 6:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $252.73
Real-time Price: $253.00 info
Change: +$0.270 (+0.11%) info
Market Cap: $37.072B info
BIIB
Oct 02, 2026, 11:20 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $221.12
Real-time Price: $253.00 info
Change: +$31.88 (+14%) info
Market Cap: $37.072B info